Masimo Sees FY24 Healthcare Revenues Up 9.4%, Growth Score A Forecasts 23.9%
Masimo’s Healthcare segment accounted for 66.6% of FY24 revenues, rising 9.4% year-over-year, while its Non-healthcare segment declined 9.5% to 33.4% of revenues. The company has a Zacks #2 Rank, VGM Score B and a Growth Style Score A forecasting 23.9% earnings growth with consensus EPS raised to $5.45.
1. Segment Performance
Irvine, CA-based Masimo saw Healthcare revenues account for 66.6% of FY24 revenues, a 9.4% increase year-over-year, while Non-healthcare revenues comprised 33.4% of sales, declining 9.5% from FY23.
2. Zacks Rank and Style Scores
Masimo holds a Zacks #2 (Buy) ranking with a VGM Score of B and a Growth Style Score of A, indicating strong combined value, growth and momentum characteristics.
3. Earnings Forecast and Analyst Revisions
Analysts have raised fiscal 2025 EPS estimates by $0.04 to $5.45 per share over the past 60 days, and Masimo has delivered an average earnings surprise of +12.4% historically, supporting its projected 23.9% earnings growth for the current fiscal year.